Edwards Lifesciences (EW) executive sells 23,145 shares at $86.42 average price

Rhea-AI Filing Summary

Edwards Lifesciences Corp executive Donald E. Bobo Jr., CVP of Strategy and Corporate Development, reported an open-market sale of common stock indirectly held through a trust. The filing shows the trust sold 23,145 shares at a weighted average price of $86.4201 per share, with individual trades executed between $86.27 and $86.57. After this transaction, the trust still holds 98,611 shares. Separate holding entries show 30,969.5756 shares held indirectly through a 401(k) plan and 22,798.2532 shares held directly, providing additional context on his overall ownership.

Insights

Insider trading and governance analyst

Routine partial insider sale via trust at around $86.42 per share.

The filing shows an open-market sale of 23,145 Edwards Lifesciences common shares at a weighted average of $86.4201 per share, executed in multiple trades between $86.27 and $86.57. The shares were held indirectly through a trust.

After the sale, the trust still holds 98,611 shares, and additional entries list 30,969.5756 shares in a 401(k) and 22,798.2532 shares held directly. This indicates a partial reduction rather than an exit, and there are no derivative exercises or tax-withholding entries in this filing.

Insider Trade Summary

Net Seller: 23,145 shares

Net Sell 3 txns

Insider BOBO DONALD E JR

Role CVP,Strategy/Corp Development

Sold 23,145 shs ($2.00M)

Type	Security	Shares	Price	Value
Sale	Common Stock	23,145	$86.4201	$2.00M
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 98,611 shares (Indirect, By Trust); Common Stock — 22,798.2532 shares (Direct); Common Stock — 30,969.5756 shares (Indirect, 401(k))

Footnotes (1)

1. F1. This transaction was executed in multiple trades at prices ranging from $86.27 to $86.57. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Key Figures

Shares sold: 23,145 shares Weighted average sale price: $86.4201 per share Trust holdings after sale: 98,611 shares +2 more

5 metrics

Shares sold 23,145 shares Open-market sale by trust on 2026-05-27

Weighted average sale price $86.4201 per share Common stock sale range $86.27–$86.57

Trust holdings after sale 98,611 shares Indirect ownership by trust after transaction

401(k) holdings 30,969.5756 shares Indirect ownership through 401(k) plan

Direct holdings 22,798.2532 shares Direct ownership balance reported

Key Terms

open-market sale, weighted average sale price, 401(k), indirect ownership

4 terms

open-market sale financial

"The filing shows the trust sold 23,145 shares at a weighted average price in an open-market sale."

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

weighted average sale price financial

"The price reported above reflects the weighted average sale price."

401(k) financial

"Separate holding entries show 30,969.5756 shares held indirectly through a 401(k) plan."

A 401(k) is a type of retirement savings plan offered by employers that allows workers to set aside a portion of their paycheck before taxes are taken out. The money saved in a 401(k) can grow over time through investments, helping individuals build funds for their future retirement. It matters to investors because it provides a tax-advantaged way to save and invest for long-term financial security.

indirect ownership financial

"The shares were held indirectly through a trust and sold at a weighted average price."

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 05/27/2026 - 07:28 PM Accepted by SEC EDGAR 05/27/2026 - 07:28 PM Learn about SEC filing dates

FAQ

What insider transaction did Edwards Lifesciences (EW) report for Donald E. Bobo Jr.?

Edwards Lifesciences reported that Donald E. Bobo Jr. executed an open-market sale of 23,145 common shares. The shares were indirectly held through a trust and sold at a weighted average price of $86.4201 per share, across multiple trades between $86.27 and $86.57.

At what price did the Edwards Lifesciences (EW) shares sell in this Form 4?

The reported weighted average sale price was $86.4201 per Edwards Lifesciences share. A footnote explains the transaction was executed in multiple trades, with individual prices ranging from $86.27 to $86.57, and the insider can provide detailed trade breakdowns upon request.

How many Edwards Lifesciences (EW) shares does the trust hold after the sale?

Following the reported sale, the trust associated with Donald E. Bobo Jr. holds 98,611 Edwards Lifesciences common shares. This figure reflects the post-transaction balance for that indirect ownership line, indicating the sale was a partial reduction rather than a full disposition.

Does Donald E. Bobo Jr. have other Edwards Lifesciences (EW) share holdings besides the trust?

Yes. In addition to the 98,611 shares held indirectly through a trust, the Form 4 lists 30,969.5756 Edwards Lifesciences shares held indirectly via a 401(k) plan and 22,798.2532 shares held directly. These figures provide context for his broader ownership position.

What is the transaction code used in this Edwards Lifesciences (EW) Form 4 filing?

The sale is coded as “S,” indicating a sale in an open market or private transaction. Two additional lines use a holding classification with unknown codes, reflecting reported balances in a 401(k) account and directly held shares rather than new buy or sell activity.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BOBO DONALD E JR

(Last) (First) (Middle)

ONE EDWARDS WAY

(Street)

IRVINE CALIFORNIA 92614

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Edwards Lifesciences Corp [ EW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CVP,Strategy/Corp Development

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/27/2026		S		23,145	D	$86.4201(1)	98,611	I	By Trust
Common Stock								22,798.2532	D
Common Stock								30,969.5756	I	401(k)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed in multiple trades at prices ranging from $86.27 to $86.57. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

	Linda J. Park, Attorney-in-Fact	05/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)